Document is current

Article History

Received: 31 May 2023

Accepted: 12 December 2023

First Online: 6 January 2024

Declarations

:

: The study was performed in accordance with the Declaration of Helsinki and ICH-GCP guidelines and approved by the Danish Data Monitoring Board (AH-2017-093), the Capital Region Scientific Ethics Committee (H-1701884617018846) and by the Danish Medicines Agency (EudraCT 2017-002101-35). Participant were included in the study only after having been given thorough written and oral information and after they had given their written consent.

: J.P.G. has been a paid Consultant for Novo Nordisk A/S. J.J.H.: has participated in advisory panels for Novo Nordisk and is a board member of Antag Therapeutics and Bainan Biotech. S.M.: has participated on advisory boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Intarcia Therapeutics, MSD, Novartis, Novo Nordisk and Sanofi and speaker’s bureau for AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk and Sanofi. S.M. has also received research grants from Novo Nordisk and Boehringer Ingelheim. N.B.J.: has participated on advisory panels for Novo Nordisk Denmark and speaker’s bureau for Novo Nordisk Denmark A/S and Boehringer Ingelheim Denmark, has received research grants from Boehringer Ingelheim, and has recently taken a position with Novo Nordisk A/S, Søborg, Denmark.